GlassScriptPhysician profile
Timothy A Piontkowski
NPI 1982706891
$14,193.39
in general payments reported to CMS, 2019-2025
53 companies · $1,300 in 2025
The $1,300 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,756 · 2020: $1,961 · 2021: $2,143 · 2022: $2,414 · 2023: $2,516 · 2024: $2,104 · 2025: $1,300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,687 · Education: $233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,687.26 |
| Education | $232.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,780.59 | 2019-2025 | Evenity, Repatha, Prolia |
| Novo Nordisk INC | $1,087.08 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Sanofi-Aventis U.S. LLC | $1,036.91 | 2019-2023 | |
| Allergan, INC. | $992.77 | 2020 | |
| Abbvie INC. | $982.20 | 2019-2025 | |
| Pfizer INC. | $919.74 | 2019-2025 | |
| Lilly USA, LLC | $865.16 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $764.80 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Astellas Pharma US INC | $681.15 | 2019-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $558.33 | 2019-2025 | Trelegy Ellipta, Bexsero, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $504.99 | 2019-2025 | Jardiance, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $412.14 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $372.72 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $356.01 | 2019-2025 | Spravato, Xarelto |
| Teva Pharmaceuticals USA, INC. | $261.01 | 2019-2021 |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $217.10 | 2019-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Otsuka America Pharmaceutical, INC. | $205.96 | 2022-2025 | Rexulti |
| Amarin Pharma, INC. | $184.16 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $180.88 | 2019-2025 | Eliquis |
| Biohaven Pharmaceutical Holding Company LTD. | $178.13 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $150.81 | 2023-2025 | Caplyta |
| Exact Sciences Corporation | $121.92 | 2023-2024 | Cologuard Collection Kit |
| Horizon Therapeutics Plc | $118.28 | 2019-2023 | Krystexxa |
| Edwards Lifesciences Corporation | $116.57 | 2025 | Sapien 3 Ultra Resilia |
| Harmony Biosciences LLC | $97.69 | 2022-2025 | Wakix |
| Takeda Pharmaceuticals U.S.A., INC. | $82.53 | 2022-2023 | Gattex, Trintellix |
| Biohaven Pharmaceuticals, INC. | $77.12 | 2021 | |
| Sanofi Pasteur INC. | $73.12 | 2022-2023 | |
| Abbott Laboratories | $68.66 | 2023-2025 | Freestyle Libre 3, Proclaim, Freestyle Libre 2 |
| Mylan Specialty L.P. | $66.36 | 2021-2024 | Yupelri |
| Cardiovascular Systems INC. | $60.52 | 2021 | |
| Esperion Therapeutics, INC. | $57.61 | 2020-2025 | Nexletol |
| Alnylam Pharmaceuticals INC. | $50.58 | 2021-2023 | Givlaari |
| Lundbeck LLC | $47.01 | 2022-2024 | Rexulti |
| Eisai INC. | $42.67 | 2020-2022 | |
| Ironwood Pharmaceuticals, INC | $41.58 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $36.67 | 2024 | Voquezna |
| Seqirus USA INC | $32.00 | 2022-2024 | Flucelvax, Fluad |
| Corcept Therapeutics | $29.99 | 2025 | Korlym |
| Axsome Therapeutics, INC. | $28.09 | 2024 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.26 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $27.16 | 2023 | Quviviq |
| Dexcom, INC. | $26.36 | 2021 | |
| Vanda Pharmaceuticals INC. | $22.31 | 2025 | Fanapt |
| Tactile Systems Technology INC | $22.05 | 2025 | Flexitouch Plus, Nimbl |
| Ucb, INC. | $19.19 | 2024 | Nayzilam |
| Hologic Sales and Service, LLC | $17.37 | 2019 | |
| Impel Pharmaceuticals INC. | $16.97 | 2022 | |
| Alexion Pharmaceuticals, INC. | $16.92 | 2023 | Strensiq |
| Pulmonx Corporation | $16.16 | 2024 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Currax Pharmaceuticals LLC | $13.94 | 2020 | |
| Indivior INC. | $13.28 | 2024 | Sublocade |
| Inari Medical, INC. | $12.81 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Piontkowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.